Portus Wealth Advisors LLC Has $81,000 Stock Position in AbbVie Inc. $ABBV

Portus Wealth Advisors LLC cut its stake in AbbVie Inc. (NYSE:ABBV) by 88.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 371 shares of the company’s stock after selling 2,902 shares during the period. Portus Wealth Advisors LLC’s holdings in AbbVie were worth $81,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Apollon Wealth Management LLC raised its holdings in AbbVie by 6.8% during the 1st quarter. Apollon Wealth Management LLC now owns 119,615 shares of the company’s stock worth $26,015,000 after purchasing an additional 7,638 shares during the last quarter. Horizon Advisory Services Inc. acquired a new position in shares of AbbVie in the 1st quarter worth approximately $211,000. Riverbend Wealth Management LLC boosted its stake in shares of AbbVie by 7.7% in the 1st quarter. Riverbend Wealth Management LLC now owns 3,853 shares of the company’s stock valued at $838,000 after purchasing an additional 276 shares during the last quarter. Red Door Wealth Management LLC boosted its stake in shares of AbbVie by 1.7% in the 1st quarter. Red Door Wealth Management LLC now owns 47,908 shares of the company’s stock valued at $10,419,000 after purchasing an additional 798 shares during the last quarter. Finally, Aspire Private Capital LLC increased its position in shares of AbbVie by 13.0% during the first quarter. Aspire Private Capital LLC now owns 9,130 shares of the company’s stock worth $1,986,000 after buying an additional 1,047 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ABBV. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a report on Tuesday, June 23rd. Piper Sandler reiterated an “overweight” rating and set a $298.00 price target on shares of AbbVie in a report on Tuesday, June 23rd. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Morgan Stanley boosted their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $253.81.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said the FDA approved Skyrizi for pediatric use in psoriatic disease, making it the first and only IL-23 inhibitor in the U.S. approved for children six years and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis. The expansion broadens the drug’s addressable market and supports long-term sales growth. Article: SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
• Positive Sentiment: AbbVie’s Apogee Therapeutics acquisition is being viewed favorably by analysts, with Canaccord raising its price target and saying the deal strengthens AbbVie’s long-term growth outlook by adding promising pipeline assets. Article: AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.
• Positive Sentiment: AbbVie is also benefiting from broader healthcare sector strength, with shares hitting new highs as investors rotate into defensive large-cap pharma names. Article: Lilly, J&J, AbbVie hit all-time highs as healthcare outperforms
• Neutral Sentiment: AbbVie announced it will host its second-quarter 2026 earnings call on July 31, which is a standard investor update and does not by itself change fundamentals. Article: AbbVie to Host Second-Quarter 2026 Earnings Conference Call
• Neutral Sentiment: Commentary pieces also highlighted AbbVie’s recent pediatric label expansions in Europe for Skyrizi and Maviret, reinforcing the company’s shift toward earlier-disease and younger-patient growth opportunities. Article: Will AbbVie’s (ABBV) Pediatric Expansions Reveal a Deeper Shift in Its Growth Mix?

AbbVie Stock Performance

ABBV stock opened at $251.52 on Monday. The stock’s 50 day simple moving average is $215.16 and its 200 day simple moving average is $219.16. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $253.35. The company has a market cap of $444.38 billion, a P/E ratio of 123.90, a price-to-earnings-growth ratio of 0.77 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the prior year, the company earned $2.46 earnings per share. The company’s quarterly revenue was up 12.4% on a year-over-year basis. Equities analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.